-
Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
•
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement with fellow Chinese firm LanssonPharm. The agreement grants Livzon exclusive rights to Lansson’s phosphodiesterase 4 (PDE4) inhibitor, LS21031, in Greater China, marking a strategic move to expand Livzon’s portfolio in the mental health space. Terms…
-
LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development
•
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced the completion of a Series A funding round worth tens of millions of yuan. The financing was led by Yipu Capital, with follow-on investments from Qianrong Capital and existing shareholder Northern Light Venture Capital. This…
